Tag Researcher Spotlight

Harsh Shah, DO

Researcher Spotlight: Harsh Shah, DO THE UNIVERSITY OF UTAHStedman Family Scholar The future of lymphoma treatment is rapidly evolving, and investigator-initiated clinical trials are helping to pave the way toward improved treatment approaches. Dr. Shah’s LRF research is focused on…

Helen Ma, MD

Researcher Spotlight: Helen Ma, MDStephanie A. Gregory Distinguished Scholar THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Veterans who have been involved in combat over the last several decades have been potentially exposed to a variety of carcinogenic elements, such as…

David Qualls, MD

Researcher Spotlight: David Qualls, MD MEMORIAL SLOAN KETTERING CANCER CENTER Immunotherapies in lymphoma aim to activate the patient’s own immune system to help target and destroy lymphoma cells. While effective, the impact of these types of therapies is often hampered…

Dai Chihara, MD

Researcher Spotlight: Dai Chihara, MD UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER Phase I trials are the first step in transitioning new drugs from the bench to the clinic. These trials are intended to evaluate the safety and tolerability of…

Elise A. Chong, MD

Researcher Spotlight: Elise A. Chong, MD University of Pennsylvania Perelman School of Medicine Chimeric antigen receptor (CAR) T-cell therapy has been an effective treatment for any patients with B-cell lymphomas who don’t respond to other therapies, producing remissions in 30…